- Home
- UROY vs CAPR Comparison
UROY vs CAPR Comparison
Compare UROY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- CAPR
- Stock Information
- Founded
- UROY 2017
- CAPR 2005
- Country
- UROY Canada
- CAPR United States
- Employees
- UROY N/A
- CAPR N/A
- Industry
- UROY
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UROY
- CAPR Health Care
- Exchange
- UROY Nasdaq
- CAPR Nasdaq
- Market Cap
- UROY 351.1M
- CAPR 332.5M
- IPO Year
- UROY N/A
- CAPR N/A
- Fundamental
- Price
- UROY $2.68
- CAPR $17.79
- Analyst Decision
- UROY Strong Buy
- CAPR Strong Buy
- Analyst Count
- UROY 2
- CAPR 7
- Target Price
- UROY $5.60
- CAPR $39.29
- AVG Volume (30 Days)
- UROY 2.2M
- CAPR 1.1M
- Earning Date
- UROY 12-11-2024
- CAPR 11-13-2024
- Dividend Yield
- UROY N/A
- CAPR N/A
- EPS Growth
- UROY N/A
- CAPR N/A
- EPS
- UROY 0.05
- CAPR N/A
- Revenue
- UROY $30,916,580.00
- CAPR $23,228,045.00
- Revenue This Year
- UROY N/A
- CAPR N/A
- Revenue Next Year
- UROY $72.53
- CAPR $135.53
- P/E Ratio
- UROY $55.04
- CAPR N/A
- Revenue Growth
- UROY 208.26
- CAPR 65.33
- 52 Week Low
- UROY $1.86
- CAPR $2.90
- 52 Week High
- UROY $3.76
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- UROY 49.79
- CAPR 47.77
- Support Level
- UROY $2.62
- CAPR $17.21
- Resistance Level
- UROY $2.83
- CAPR $19.47
- Average True Range (ATR)
- UROY 0.16
- CAPR 1.64
- MACD
- UROY -0.01
- CAPR -0.38
- Stochastic Oscillator
- UROY 54.55
- CAPR 28.33
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.